General Information
Acta Pharmaceutica (AP) is a quarterly journal dealing with all branches of pharmaceutical and related sciences, respecting openness, authenticity, ethics and transparency. It is an international, scientific, multidisciplinary journal, which brings articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With a strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice, in the form of original research papers, preliminary and short communications, and reviews (systematic/critical, mini reviews, meta-analysis and bibliometric-analysis reviews). Book reviews are published also.
Acta Pharmaceutica is a single-blind, peer-reviewed journal (at least two independent referees after the desk pre-review). It is also an open access journal (“gold” OA) with “early bird” platform. To reach the highest standards in publication ethics all the parties (authors, editors, reviewers) are required to behave responsibly and ethically. This implies submittance by authors on an exclusive basis, of only their own and new data; novelty and originality are prioritized. Also, secure handling of confidential data by reviewers and editors is a must.
All submitted manuscripts should conform to generally accepted usage in composition of research papers. For technical requirements author should consult Information for authors and the recent issues.
Submission of materials generated by AI is discouraged. Neither is allowed to submit paper-mills-produced materials. Otherwise retraction policy might be activated.
The use of official institutional e-mail address during paper submittance and afterwards is strongly recommended. The authors with no official institutional e-mail address who use some of the restricted domains (like rediffmail.com, qq.com, hotmail.com, yahoo.com, outlook.com, 126.com, 263.net, 163.com, gmail.com, yeah.net, and more alike), need to attach the Authentication letter issued and signed by the affiliating institution, during submission process (template provided at the end of Instructions for Authors).
Numerous topics are covered by Acta Pharmaceutica from from analytics of drugs, biochemistry, biophysics, cell biology, clinical pharmacy, cosmetology, drug design/delivery/disposition and stability, drug metabolism, genetics, medicine (including diagnostics and therapy), molecular modelling/docking studies, peptide and protein chemistry/protein design, pharmaceutical biology, pharmaceutical chemistry/medicinal chemistry, pharmaceutical technology/formulation studies, pharmaceutics/biopharmacy, pharmacodynamics, pharmacoepidemiology/pharmacoeconomics, pharmacognosy, pharmacokinetics, pharmacology, pharmacovigilance, radiopharmaceuticals, social pharmacy, toxicology, and others.
AP is indexed in numerous world top international bibliographic bases, like Clarivate™ Web of Science Core Collection (SCI-Expanded, JCR/Science Edition, etc.), EMBASE/Excerpta Medica, MEDLINE/PubMed, Scopus/SCImago, and others. It is a Q2 journal (Pharmaceutical Sciences) according to SCImago.
Publication fee payment for publishing articles in Acta Pharmaceutica is mandatory for all articles accepted for publication. Publication fee is 1500 € per manuscript (excl. VAT). Authors will receive an invoice right after acceptance of their paper which will not be published before the fee has been paid. Prices are subject to change without notice. Payments should be made to the invoice of the publisher, Croatian Pharmaceutical Society, Masarykova 2, HR-10000 Zagreb, Croatia. More technical details are given in the Acceptance letter.
The open access articles are distributed under the terms of the non-commercial use of the article governed by the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0).